• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

    9/9/25 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email

    XI'AN, China, Sept. 9, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 24 months with a total contract value of US$18 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's innovative second-generation Apple Series health products across Greater China, tapping into significant market potential in the weight management and metabolic health sectors.

    Leveraging advanced low-temperature extraction technology, BON's second-generation Apple Series delivers 80% higher bioactivity than its predecessor by improving the efficiency of the active ingredient extraction. This technological allows for a proprietary formulation that combines highly active apple polyphenols with plant protein, demonstrating strong efficacy in weight management and metabolic health applications.

    After decades of evolution, protein supplements have become mainstream health essentials, integral to fitness regimens, immune support programs, and longevity-focused nutrition plans. BON's innovative incorporation of apple polyphenols into protein supplements delivers clinically validated benefits, including improved lipid metabolism, enhanced body composition, and reduced of age-related muscle loss - positioning the product at the intersection of established market needs and innovative functionality with significant growth potential.

    Early market validation is encouraging, with comparable apple polyphenol blends generating over $40 million in monthly sales. Industry analysts attribute this to consumers' growing willingness to pay for scientifically validated "nutraceutical products." BON management expressed confidence in achieving strong market performance given the competitive advantages of its second-generation formulation.

    "We have both the responsibility and capability as a global leader in apple polyphenols to develop superior health solutions," stated Mr. Yongwei Hu, Chairman and CEO of BON. "Through our vertically integrated supply chain  - from raw materials to production - we are well-positioned to lead the rapidly growing metabolic health segment. The enhanced bioactivity of our second-generation apple polyphenols is expected to drive significant revenue and profit growth across nutraceutical and functional food markets, enhancing shareholder value and delivering strong returns."

    About Bon Natural Life Limited ("BON")

    BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com. 

    For more information, please contact:

    Cindy Liu | IR       

    Email: [email protected] 

    Safe Harbor Statement

    This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    Cision View original content:https://www.prnewswire.com/news-releases/bon-announces-18-million-cooperation-agreement-for-innovative-second-generation-apple-series-health-products-302550246.html

    SOURCE Bon Natural Life Limited

    Get the next $BON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

    XI'AN, China, Sept. 9, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 24 months with a total contract value of US$18 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's innovative second-generation Apple Series health products across Greater China, tapping into significant market potential in the weight management and m

    9/9/25 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

    XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate that these compounds exhibit significant activity in weight management, with key efficacy indicators outperforming current mainstream weight-managing drugs, injecting new momentum into global R&D of weight-managing drugs. With a worsening global obesity crisis, the weight-manag

    9/2/25 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Announces Reciept of Nasdaq Compliance Letter

    XI'AN, China, Aug. 5, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Panel also advised the Company that it will be subject to a one-year Discretionary Panel M

    8/5/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    SEC Filings

    View All

    SEC Form F-3 filed by Bon Natural Life Limited

    F-3 - Bon Natural Life Ltd (0001816815) (Filer)

    10/15/25 8:37:33 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    9/29/25 9:27:41 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    9/9/25 8:32:07 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    Bon Natural Life Limited Announces Change to Board Composition

    XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

    6/30/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Financials

    Live finance-specific insights

    View All

    Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

    Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

    2/7/23 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

    7/28/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

    1/28/22 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care